Literature DB >> 15104246

Disorazol A1, a highly effective antimitotic agent acting on tubulin polymerization and inducing apoptosis in mammalian cells.

Yasser A Elnakady1, Florenz Sasse, Heinrich Lünsdorf, Hans Reichenbach.   

Abstract

Disorazol A1, a macrocyclic polyketide compound that is produced by the myxobacterium Sorangium cellulosum showed a remarkably high cytostatic activity. It inhibited the proliferation of different cancer cell lines including a multidrug-resistant KB line at low picomolar levels. In presence of disorazol A1, the nuclei of the cells increased in size and the cells often became multinucleate. Low concentrations of disorazol (<100 pM) induced an apoptotic process, characterized by enhanced capase-3 activity and DNA laddering, and abnormal, multipolar mitotic spindles. Low concentrations also induced an accumulation of p53 protein in the nucleus. At higher concentrations, we observed an accumulation of the cells in the G2/M-phase of the cell cycle, and a depletion of microtubules. In vitro, disorazol A1 inhibited the polymerization of tubulin in a concentration-dependent manner and independently of microtubule-associated proteins. Correspondingly it induced a complete depolymerization of microtubules prepared in vitro. Formation of defined degradation structures was not observed. Disorazol is a novel, highly effective antimitotic agent. Efforts are going on to develop it as an anticancer drug.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15104246     DOI: 10.1016/j.bcp.2003.10.029

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

Review 1.  Analysis of myxobacterial secondary metabolism goes molecular.

Authors:  Helge B Bode; Rolf Müller
Journal:  J Ind Microbiol Biotechnol       Date:  2006-02-21       Impact factor: 3.346

2.  Total synthesis of (-)-CP2-disorazole C1.

Authors:  Chad D Hopkins; John C Schmitz; Edward Chu; Peter Wipf
Journal:  Org Lett       Date:  2011-07-08       Impact factor: 6.005

3.  Identifying a resistance determinant for the antimitotic natural products disorazole C1 and A1.

Authors:  John S Lazo; Celeste E Reese; Andreas Vogt; Laura L Vollmer; Carolyn A Kitchens; Eckhard Günther; Thomas H Graham; Chad D Hopkins; Peter Wipf
Journal:  J Pharmacol Exp Ther       Date:  2009-12-15       Impact factor: 4.030

4.  Mitotic slippage in non-cancer cells induced by a microtubule disruptor, disorazole C1.

Authors:  Fengfeng L Xu; Youssef Rbaibi; Kirill Kiselyov; John S Lazo; Peter Wipf; William S Saunders
Journal:  BMC Chem Biol       Date:  2010-02-11

Review 5.  Isolation, biology and chemistry of the disorazoles: new anti-cancer macrodiolides.

Authors:  Chad D Hopkins; Peter Wipf
Journal:  Nat Prod Rep       Date:  2009-03-11       Impact factor: 13.423

6.  Fusarisetins: Structure-function studies on a novel class of cell migration inhibitors.

Authors:  Eduardo J E Caro-Diaz; Aereas Aung; Jing Xu; Shyni Varghese; Emmanuel A Theodorakis
Journal:  Org Chem Front       Date:  2014-04-01       Impact factor: 5.281

7.  Microtubule binding and disruption and induction of premature senescence by disorazole C(1).

Authors:  Marni Brisson Tierno; Carolyn A Kitchens; Bethany Petrik; Thomas H Graham; Peter Wipf; Fengfeng L Xu; William S Saunders; Brianne S Raccor; Raghavan Balachandran; Billy W Day; Jane R Stout; Claire E Walczak; Alexander P Ducruet; Celeste E Reese; John S Lazo
Journal:  J Pharmacol Exp Ther       Date:  2008-12-09       Impact factor: 4.030

8.  Pretubulysin: from hypothetical biosynthetic intermediate to potential lead in tumor therapy.

Authors:  Jennifer Herrmann; Yasser A Elnakady; Romina M Wiedmann; Angelika Ullrich; Manfred Rohde; Uli Kazmaier; Angelika M Vollmar; Rolf Müller
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

9.  Genetic engineering and heterologous expression of the disorazol biosynthetic gene cluster via Red/ET recombineering.

Authors:  Qiang Tu; Jennifer Herrmann; Shengbiao Hu; Ritesh Raju; Xiaoying Bian; Youming Zhang; Rolf Müller
Journal:  Sci Rep       Date:  2016-02-15       Impact factor: 4.379

10.  Design, Synthesis and Antitumor Activity of Novel link-bridge and B-Ring Modified Combretastatin A-4 (CA-4) Analogues as Potent Antitubulin Agents.

Authors:  Yong-Tao Duan; Ruo-Jun Man; Dan-Jie Tang; Yong-Fang Yao; Xiang-Xiang Tao; Chen Yu; Xin-Yi Liang; Jigar A Makawana; Mei-Juan Zou; Zhong-Chang Wang; Hai-Liang Zhu
Journal:  Sci Rep       Date:  2016-05-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.